Gameto – Weekly Recap

Gameto, a women’s health biotechnology company focused on fertility and menopause, reported a series of late‑stage clinical, financing, and visibility milestones this week that underscore its maturation from early-stage developer to a more advanced pipeline company. The update provides a broad look at progress in its lead fertility platform, Fertilo, expansion into menopause care through its Ameno program, and continued strengthening of its financial and strategic position.

Across several disclosures, Gameto emphasized that Fertilo, its in vitro maturation (IVM) platform designed to make IVF faster and more accessible, is now in final Phase III clinical trials. More than 100 couples have been treated, with at least nine births reported and the first babies born through the platform outside the U.S. The company highlighted a notable real-world case in Australia, where a patient with an ovarian condition – including a pilot involving a patient with polycystic ovary syndrome – achieved pregnancy after years of unsuccessful attempts using traditional fertility methods. Patients in these pilots reported fewer injections and reduced side effects relative to conventional stimulation protocols, suggesting potential improvements in treatment burden if results are replicated at scale.

Gameto is also using the American Society for Reproductive Medicine (ASRM) 2025 meeting as a key platform to deepen engagement with clinicians and key opinion leaders. The company is showcasing Fertilo’s embryology workflow through live demonstrations aimed at illustrating how the technology integrates into existing IVF laboratory processes. In parallel, Gameto is presenting new data and scientific talks on Ameno, its next‑generation hormone-sensitive ovarian implant intended to transform menopause care. Ameno, which leverages engineered ovarian-like cells and controlled androgen release, has been backed by a $10 million grant from ARPA-H’s Sprint for Women’s Health Initiative, providing non-dilutive funding and external validation of the program.

Beyond Fertilo and Ameno, Gameto continues to build a broader platform with Deovo, an early program aimed at advancing research and drug testing for ovarian disease. The company also reported that it has raised a total of $127 million in funding, including a Series C round led by Overwater Ventures, supporting concurrent advancement of multiple assets. Recognition with the “Future of Fertility” award at the World Fertility Awards further enhances Gameto’s profile within reproductive medicine.

Collectively, these developments indicate sustained progress in late-stage fertility trials, meaningful steps toward clinical development in menopause, and a strengthening financial base. If ongoing trials confirm efficacy and safety, and regulatory pathways advance as anticipated, Gameto appears well-positioned to compete in the underpenetrated women’s health and reproductive biotechnology segment, with potential future revenue streams in fertility, menopause therapy, and ovarian disease research. Overall, the week marked a notably constructive period for the company, characterized by clinical advancement, external validation, and growing industry visibility.